Sarasin & Partners LLP Boosts Holdings in Zoetis Inc. $ZTS

Sarasin & Partners LLP increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 2.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,649,946 shares of the company’s stock after acquiring an additional 38,367 shares during the quarter. Zoetis comprises approximately 2.3% of Sarasin & Partners LLP’s portfolio, making the stock its 18th largest holding. Sarasin & Partners LLP owned about 0.37% of Zoetis worth $236,041,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Savvy Advisors Inc. boosted its holdings in shares of Zoetis by 54.0% in the second quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock valued at $495,000 after acquiring an additional 1,114 shares during the period. Sound Income Strategies LLC boosted its stake in Zoetis by 54.3% during the 2nd quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock worth $67,000 after purchasing an additional 152 shares during the period. Canoe Financial LP boosted its stake in Zoetis by 859.0% during the 2nd quarter. Canoe Financial LP now owns 13,369 shares of the company’s stock worth $2,085,000 after purchasing an additional 11,975 shares during the period. Strs Ohio purchased a new position in Zoetis during the 1st quarter worth $22,891,000. Finally, Chicago Partners Investment Group LLC increased its stake in Zoetis by 67.0% in the second quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company’s stock valued at $750,000 after purchasing an additional 1,961 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ZTS shares. Morgan Stanley set a $160.00 price target on Zoetis in a report on Thursday. KeyCorp started coverage on Zoetis in a research report on Thursday, November 20th. They set a “sector weight” rating for the company. Argus reiterated a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Barclays assumed coverage on Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target for the company. Finally, UBS Group decreased their price target on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a report on Wednesday, November 5th. Six investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $160.18.

Zoetis Stock Performance

Shares of ZTS stock opened at $122.34 on Friday. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. The stock has a 50 day simple moving average of $128.86 and a 200-day simple moving average of $144.48. The company has a market cap of $53.91 billion, a price-to-earnings ratio of 20.60, a price-to-earnings-growth ratio of 2.66 and a beta of 0.97. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.40.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.Zoetis’s quarterly revenue was up .5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 20th. This is an increase from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s dividend payout ratio (DPR) is 33.67%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.